Please wait while the formulary information is being retrieved.
Drug overview for AEMCOLO (rifamycin sodium):
Generic name: rifamycin sodium (RIF-a-MYE-sin)
Drug class: Rifamycins
Therapeutic class: Anti-Infective Agents
Rifamycin sodium is a rifamycin antibiotic.
No enhanced Uses information available for this drug.
Generic name: rifamycin sodium (RIF-a-MYE-sin)
Drug class: Rifamycins
Therapeutic class: Anti-Infective Agents
Rifamycin sodium is a rifamycin antibiotic.
No enhanced Uses information available for this drug.
DRUG IMAGES
No Image Available
The following indications for AEMCOLO (rifamycin sodium) have been approved by the FDA:
Indications:
Traveler's diarrhea due to noninvasive strain of Escherichia coli
Professional Synonyms:
Traveler's diarrhea due to noninvasive E. coli
Indications:
Traveler's diarrhea due to noninvasive strain of Escherichia coli
Professional Synonyms:
Traveler's diarrhea due to noninvasive E. coli
The following dosing information is available for AEMCOLO (rifamycin sodium):
Dosage of rifamycin sodium is expressed in terms of rifamycin.
Administer orally without regard to food. Do not administer with alcohol. Administer each dose of rifamycin with 6-8 ouncesof liquid.
Swallow rifamycin tablets whole; do not crush, break, or chew. Store the tablets at 20-25oC (excursions permitted to 15-30oC).
Swallow rifamycin tablets whole; do not crush, break, or chew. Store the tablets at 20-25oC (excursions permitted to 15-30oC).
No dosing information available.
No generic dosing information available.
The following drug interaction information is available for AEMCOLO (rifamycin sodium):
There are 1 contraindications.
These drug combinations generally should not be dispensed or administered to the same patient. A manufacturer label warning that indicates the contraindication warrants inclusion of a drug combination in this category, regardless of clinical evidence or lack of clinical evidence to support the contraindication.
| Drug Interaction | Drug Names |
|---|---|
| Live Typhoid Vaccine/Antimicrobials SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: The antimicrobial may be active against the organism in the live-vaccine. Antimicrobial therapy may prevent the vaccine organism from replicating enough to trigger an immune response.(1) CLINICAL EFFECTS: Vaccination may be ineffective. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Do not give oral typhoid vaccine until 72 hours after the last dose of antimicrobial. If possible, to optimize vaccine effectiveness, do not start antibacterial drugs for 72 hours after the last dose of oral typhoid vaccine. A longer interval should be considered for long-acting antimicrobials, such as azithromycin.(3) DISCUSSION: Because antimicrobial therapy may prevent sufficient vaccine-organism replication to generate an immune response, the manufacturer of live-attenuated typhoid vaccine and the Centers for Disease Control (CDC) state that the vaccine should not be administered to patients receiving antimicrobial therapy.(1-3) |
VIVOTIF |
There are 1 severe interactions.
These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.
| Drug Interaction | Drug Names |
|---|---|
| Fecal Microbiota Spores/Antibiotics SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Fecal microbiota spores is a suspension of live bacterial spores, which may be compromised by concurrent use of antibiotics.(1) CLINICAL EFFECTS: Antibiotics may decrease the effectiveness of fecal microbiota spores.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Antibiotics should not be used concurrently with fecal microbiota spores. Antibacterial treatment should be completed for 2 to 4 days before initiating treatment with fecal microbiota spores.(1) DISCUSSION: Antibiotics may compromise the effectiveness of fecal microbiota spores. |
VOWST |
There are 0 moderate interactions.
The following contraindication information is available for AEMCOLO (rifamycin sodium):
Drug contraindication overview.
*Known hypersensitivity to rifamycin, any of the other rifamycin class antimicrobial agents (e.g., rifaximin), or any of the components.
*Known hypersensitivity to rifamycin, any of the other rifamycin class antimicrobial agents (e.g., rifaximin), or any of the components.
There are 0 contraindications.
There are 1 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Clostridioides difficile infection |
There are 0 moderate contraindications.
The following adverse reaction information is available for AEMCOLO (rifamycin sodium):
Adverse reaction overview.
Most common adverse reactions (incidence >2%) are headache and constipation.
Most common adverse reactions (incidence >2%) are headache and constipation.
There are 1 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. | None. |
| Rare/Very Rare |
|---|
|
Clostridioides difficile infection |
There are 5 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Constipation Headache disorder |
Acute abdominal pain Dyspepsia Fever |
| Rare/Very Rare |
|---|
| None. |
The following precautions are available for AEMCOLO (rifamycin sodium):
Safety and efficacy of rifamycin have not been established in pediatric patients <18 years of age.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
Data are not available regarding the use of rifamycin in pregnant women. Due to minimal systemic absorption, fetal exposure is not expected with maternal use. In animal reproductive studies, treatment with rifamycin in rats during organogenesis resulted in maternal toxicity, decreased fetal weight, and teratogenicity at dosages approximately 1000-25,000 times the maximum plasma concentration and systemic exposure (based on AUC), respectively. In rabbits, treatment with rifamycin resulted in maternal toxicity, decreased fetal weight, and slight delays in fetal ossification at dosages approximately 10 times the maximum human plasma concentration.
It is not known whether rifamycin is distributed into human milk, affects human milk production, or affects the breast-fed infant. Because systemic absorption of rifamycin in humans is negligible following oral administration, the level of exposure to a breastfed infant through breastmilk is expected to be limited. Benefits of breastfeeding and the importance of rifamycin to the woman should be considered along with the potential adverse effects on the breast-fed child from the drug or from the underlying maternal condition.
The manufacturer makes no specific dosage recommendations for geriatric patients. Experience in patients 65 yearsof age and older with travelers' diarrhea is insufficient to determine whether they respond differently than younger subjects. Other reported clinical experience has not identified differences in response.
The following prioritized warning is available for AEMCOLO (rifamycin sodium):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for AEMCOLO (rifamycin sodium)'s list of indications:
| Traveler's diarrhea due to noninvasive escherichia coli | |
| A04.2 | Enteroinvasive escherichia coli infection |
| A04.4 | Other intestinal escherichia coli infections |
| A09 | Infectious gastroenteritis and colitis, unspecified |
Formulary Reference Tool